Recruiting
A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT07851259· Phase 2· Genentech, Inc.· Source
Recruiting
A Study in Adults With Geographic Atrophy
NCT07606365· Phase 2· Sitala Bio LTD· Source
Contact: David Almeida (principal investigator)
Recruiting
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
NCT07770828· Phase 3· Ocugen· Source
Contact: Bethany Scott
Recruiting
A Phase 2 Study of NT-101 Topical in Patients With Wet AMD
NCT07811726· Phase 2· NexThera Co., Ltd.· Source
Contact: Almeida RP David, M.D.
Recruiting
Study of ALK-001 on the Progression of Stargardt Disease
NCT07419334· Phase 3· Alkeus Pharmaceuticals, Inc.· Source
Contact: Bethany Bielak-Scott
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
NCT07496567· Phase 2/3· EyeBiotech Ltd.· Source
Contact: Study Coordinator
Active, not recruiting
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449936· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Active, not recruiting
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related Cataract
NCT07395986· Phase 2· Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.· Source
Active, not recruiting
Ocular Proteomics Testing In Chronic Atrophy
NCT07298291· ClinOmicsAI· Source
Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
NCT06990399· Phase 3· Kodiak Sciences Inc· Source
Contact: Kodiak Sciences Inc
Recruiting
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT07064759· Phase 3· 4D Molecular Therapeutics· Source
Contact: 4DMT Patient Advocacy
Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
NCT06996080· Phase 3· Kodiak Sciences Inc· Source
Contact: Kodiak Sciences Inc
Not yet recruiting
A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration
NCT06470373· Phase 3· Rophibio, Inc.· Source
Contact: Bethany Scott
Recruiting
Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
NCT06924021· University of Wisconsin, Madison· Source
Contact: David Almeida (principal investigator)
Active, not recruiting
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988· Phase 3· 4D Molecular Therapeutics· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
NCT06770933· Phase 2· Vantage Biosciences Ltd· Source
Active, not recruiting
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
NCT06779773· Astellas Pharma Global Development, Inc.· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
NCT06495918· Phase 3· Ocular Therapeutix, Inc.· Source
Active, not recruiting
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
NCT06668064· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)
NCT06817343· Phase 1· Exegenesis Bio· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
NCT06556368· Phase 3· Kodiak Sciences Inc· Source
Active, not recruiting
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
NCT06401044· Phase 1/2· Amgen· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
NCT06223958· Phase 3· Ocular Therapeutix, Inc.· Source
Active, not recruiting
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153· Phase 1/2· Alcon Research· Source
Active, not recruiting
4D-150 in Patients With Diabetic Macular Edema
NCT05930561· Phase 2· 4D Molecular Therapeutics· Source
Active, not recruiting
Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema
NCT05608837· Phase 2· Quan Dong Nguyen· Source
Active, not recruiting
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
NCT04853251· Phase 4· Genentech, Inc.· Source